Literature-reported formulation composition
Component: TNT-b10 | mol%: 20 | Role: Ionizable lipid
sales@dcchemicals.com
TNT-b10
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Literature-reported formulation composition
Component: DOPE | mol%: 30 | Role: Helper phospholipid
Literature-reported formulation composition
Component: Cholesterol | mol%: 40 | Role: Sterol
Literature-reported formulation composition
Component: DMG-PEG2000 | mol%: 0 | Role: PEG lipid
Literature-reported formulation composition
Component: Reported total | mol%: 90 | Role: Source values retained
Reported observation
Literature-reported In-vitro luciferase expression F25 was approximately two-fold higher than the initial formulation Hep3B cells, TNT-b10 LLNs · Initial TNT-b10 formulation PDF p. 3, Fig. 3.
Reported observation
Literature-reported In-vitro dose response Dose-dependent luciferase expression at 25-200 ng/well O-TNT-b10 LLNs in Hep3B cells · TNT-a10 LLNs PDF p. 4, Fig. 4B.
Reported observation
Literature-reported Relative delivery Approximately 10-fold higher than TNT-a10 under the same formulation ratio O-TNT-b10 LLNs in Hep3B cells · TNT-a10 LLNs PDF pp. 4-5, Fig. 4B and text.
Reported observation
Literature-reported In-vivo biodistribution Strong liver and spleen luciferase expression; IV spleen signal was more than 10-fold higher than liver signal O-TNT-b10 FLuc mRNA LLNs, 0.5 mg/kg · Free mRNA and other injection routes PDF pp. 5-6, Fig. 6.
Reported observation
Literature-reported Formulation stability Stable for at least four weeks after PEGylation O-TNT-b10 LLNs · Non-PEGylated F25 PDF p. 3-4, Fig. 4A.
Reported observation
Local structural transformation The paper attributes the higher activity of TNT-b10 over TNT-a10 to changing the positions of the hydroxyl and amino groups; this is a matched structural comparison under the study's formulation conditions. · PDF pp. 2-3, Figs. 1-2.
Reported observation
Organ distribution The optimized PEGylated formulation produced strong liver and spleen signal, with a spleen-biased signal after IV administration. · PDF pp. 5-6, Fig. 6.